Sphere Fluidics
Sphere Fluidics’ platforms are built on over a decade of scientific and engineering research and development. Originally spun out from the University of Cambridge, they specialize in single-cell analysis and isolation platforms – helping you to find your really important cells.
Latest Sphere Fluidics Content
Product News
Sphere Fluidics Expands Cyto-Mine Capabilities To Meet cGMP Requirements for Drug Manufacture Workflows
Sphere Fluidics has announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice regulations enforced by the US FDA.
Product News
Sphere Fluidics’ Pico-Mine platform chosen by Biosyntia to accelerate synthetic biology and metabolic workflows
Sphere Fluidics announced Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.
Product News
Sphere Fluidics Updates Brand Identity To Align With Ambitious, Global Commercial Growth Strategy
Sphere Fluidics announced the introduction of new branding to align with its ambitious global commercial growth strategy.
Product News
Sphere Fluidics Begins Work With Partners on 3DSecret Program To Investigate Mechanisms of Metastasis in Cancer
Sphere Fluidics, a company developing single-cell analysis systems underpinned by its patented picodroplet technology, has announced its involvement in 3DSecret.
Webinar
Novel Bioassays in Picodroplets for Single-Cell Analysis
On-Demand
Speaking at the Advances in Drug Discovery & Development 2022, Romina Durigon from Sphere Fluidics discusses novel bioassays in picodroplets for single-cell analysis.
Advertisement
